Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Sugary drinks stood out in this stomach cancer study, but diet drinks did not

21

Sep 2026

Sugary drinks stood out in this stomach cancer study, but diet drinks did not

In two large US prospective cohorts, consuming more than one sugar-sweetened beverage a day was associated with higher gastric cancer incidence compared with consuming less than one serving a month. Artificially sweetened beverages were not associated with gastric cancer incidence, and the authors called for further studies to confirm the findings and clarify possible biological mechanisms.

Measles outbreaks may reveal more than gaps in vaccination

21

Sep 2026

Measles outbreaks may reveal more than gaps in vaccination

A commentary in Human Vaccines & Immunotherapeutics argues that measles outbreaks can serve as a sensitive indicator of weaknesses in vaccination coverage, surveillance, health equity, community trust, and broader immunization systems. The authors contend that pursuing measles eradication could also strengthen routine immunization, laboratory capacity, outbreak preparedness, and health-system resilience.

A 194-country analysis reveals gaps in how late childhood vaccinations are tracked

21

Sep 2026

A 194-country analysis reveals gaps in how late childhood vaccinations are tracked

A global analysis of WHO/UNICEF data from 194 countries found wide variation in countries’ ability to record delayed childhood vaccinations, with 64% of reporting countries saying they could capture late doses in 2022. Following birth cohorts over time and adding delayed MCV1 doses raised median coverage estimates by 3.6 to 5.1 percentage points across available cohort years, though incomplete and inconsistent reporting limited confidence in some estimates.

Why wanting alcohol may matter more than liking it

21

Sep 2026

Why wanting alcohol may matter more than liking it

Researchers found that self-reported wanting was more strongly associated with drinking motives than liking, with the strongest links seen for coping motives and higher alcohol-use severity. The cross-sectional study of 446 adults also linked greater wanting, coping motives, and higher AUDIT scores with stronger intentions to quit or reduce drinking, but it could not establish cause or direction.

Older adults with higher polyphenol intake were less likely to have mild cognitive impairment

20

Sep 2026

Older adults with higher polyphenol intake were less likely to have mild cognitive impairment

In a cross-sectional study of 92 older Italian memory-clinic patients, higher habitual intake of total dietary (poly)phenols and several specific subclasses was associated with a lower likelihood of mild cognitive impairment (MCI). Total (poly)phenol intake was not associated with cognitive test performance or circulating inflammatory biomarkers, and the authors cautioned that the small observational study cannot establish causality.

Why might a higher BMI at 20 be linked to lower breast cancer risk later in life?

20

Sep 2026

Why might a higher BMI at 20 be linked to lower breast cancer risk later in life?

A large UK cohort study found that higher BMI at age 20 was associated with lower postmenopausal breast cancer risk, while higher BMI in later adulthood was linked to increased risk. Lower VAS percentage mammographic density appeared to explain part of the early-adulthood association, while fibroglandular volume showed a different relationship with life-course adiposity.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.